ROAR (anaplastic thyroid cancer cohort)
Turned the most lethal thyroid cancer from a months-long death sentence into a treatable disease for the third of patients whose tumours carry a BRAF mutation.
ORR 56%; median OS 15 months with 12-month OS 52% versus historical medians under 6 months (updated analysis, Annals of Oncology 2022). FDA approval May 2018, the first targeted therapy for ATC; neoadjuvant use now enables surgery in previously unresectable tumours.
- 56 out of 100 people had their tumour shrink with Dabrafenib + trametinib.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: BRAF V600E-mutant anaplastic thyroid cancer: dabrafenib + trametinib. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (BRAF); the result should not be assumed for people whose cancer does not have it.
- Only 36 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- PersonKeith T. Flaherty
Shares Dabrafenib + trametinib, BRAF, Small-molecule kinase inhibitors.
- TrialDECISION
Shares BRAF, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialCOMBI-AD
Shares Dabrafenib + trametinib, BRAF.
- PairingMAPK inhibitor redifferentiation → radioiodine
Shares Dabrafenib + trametinib, Thyroid cancer, Small-molecule kinase inhibitors.
- PairingBRAF inhibitor + MEK inhibitor
Shares Dabrafenib + trametinib, BRAF.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Dabrafenib + trametinib, BRAF.
- TrialDREAMseq (ECOG-ACRIN EA6134)
Shares Dabrafenib + trametinib, BRAF.
- TrialARROW (thyroid cohorts)